Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia

Archives of General Psychiatry

Volumn 60, Issue 5, 2003, Pages 466-472

  Dickerson, Faith B ^a   Boronow, John J ^a   Stallings, Cassie ^a   Origoni, Andrea E ^a   Ruslanova, Inna ^a   Yolken, Robert H ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VIRUS 1 ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOMEGALOVIRUS; DISABILITY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MEMORY; NONHUMAN; SCHIZOPHRENIA; SEROLOGY; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AMBULATORY CARE; ANTIBODIES, VIRAL; CENTRAL NERVOUS SYSTEM VIRAL DISEASES; COGNITION DISORDERS; DISCRIMINANT ANALYSIS; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN G; MALE; MEMORY DISORDERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUROPSYCHOLOGICAL TESTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0038643578     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.60.5.466     Document Type: Article

References (64)

1. Regier DA, Narrow WE, Rae DS, Manderscheid RW, Locke BZ, Goodwin FK. The de facto US mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993;50:85-94.
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426-445.
3. Hyde TM, Nawroz S, Goldberg TE, Bigelow LB, Strong D, Ostrem JL, Weinberger DR, Kleinman JE. Is there cognitive decline in schizophrenia? a crosssectional study. Br J Psychiatry. 1994;164:494-500.
4. Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156:1328-1335.
5. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches [published correction appears in Biol Psychiatry. 2002;51:346]. Biol Psychiatry. 2001;50:884-897.
6. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry. 1999;56:749-754.
7. Tamminga CA, Buchanan RW, Gold JM. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int Clin Psychopharmacol. 1998; 13(suppl 3):S21-S26.
8. Aleman A, Hijman R, de Haan EH, Kahn RS. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry. 1999;156:1358-1366.
9. Weickert TW, Goldberg TE, Gold JM, Bigelow LB, Egan MF, Weinberger DR. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry. 2000;57:907-913.
10. Kremen WS, Seidman LJ, Faraone SV,Tsuang MT. Intelligence quotient and neuropsychological profiles in patients with schizophrenia and in normal volunteers. Biol Psychiatry. 2001;50:453-462.
11. Liddle PF. Cognitive impairment in schizophrenia: its impact on social functioning. Acta Psychiatr Scand Suppl. 2000;400:11-16.
12. Dickerson F, Boronow JJ, Ringel N, Parente F. Neurocognitive deficits and social functioning in outpatients with schizophrenia. Schizophr Res. 1996;21:75-83.
13. Silverstein SM, Schenkel LS, Valone C, Nuernberger SW. Cognitive deficits and psychiatric rehabilitation outcomes in schizophrenia. Psychiatr Q. 1998;69:169-191.
14. Bellack AS, Gold JM, Buchanan RW. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr Bull. 1999;25:257-274.
15. Hawkins KA, Mohamed S, Woods SW. Will the novel antipsychotics significantly ameliorate neuropsychological deficits and improve adaptive functioning in schizophrenia? Psychol Med. 1999;29:1-8.
16. Daheshia M, Feldman LT, Rouse BT. Herpes simplex virus latency and the immune response. Curr Opin Microbiol. 1998;1:430-435.
17. Drummond CW, Eglin RP, Esiri MM. Herpes simplex virus encephalitis in a mouse model: PCR evidence for CNS latency following acute infection. J Neurol Sci. 1994; 127:159-163.
18. Quinn JP, Dalziel RG, Nash AA. Herpes virus latency in sensory ganglia: a comparison with endogenous neuronal gene expression. Prog Neurobiol. 2000;60: 167-179.
19. Steiner I, Mador N, Reibstein I, Spivack JG, Fraser NW. Herpes simplex virus type 1 gene expression and reactivation of latent infection in the central nervous system. Neuropathol Appl Neurobiol. 1994;20:253-260.
20. Arbusow V, Schulz P, Strupp M, Dieterich M, von Reinhardstoettner A, Rauch E, Rauch E, Brandt T. Distribution of herpes simplex virus type 1 in human geniculate and vestibular ganglia: implications for vestibular neuritis. Ann Neurol. 1999; 46:416-419.
21. Liedtke W, Opalka B, Zimmermann CW, Lignitz E. Age distribution of latent herpes simplex virus 1 and varicella-zoster virus genome in human nervous tissue. J Neurol Sci. 1993;116:6-11.
22. Ehrnst A. The clinical relevance of different laboratory tests in CMV diagnosis. Scand J Infect Dis Suppl. 1996;100:64-71.
23. Tanaka-Taya K, Kondo T, Mukai T, Miyoshi H, Yamamoto Y, Okada S, Yamanishi K. Seroepidemiological study of human herpesvirus-6 and -7 in children of different ages and detection of these two viruses in throat swabs by polymerase chain reaction. J Med Virol. 1996;48:88-94.
24. Slomka MJ. Seroepidemiology and control of genital herpes: the value of type specific antibodies to herpes simplex virus. Commun Dis Rep CDR Rev. 1996; 6(3):R41-R45.
25. Schmutzhard E. Viral infections of the CNS with special emphasis on herpes simplex infections. J Neurol. 2001;248:469-477.
26. Cinque P, Marenzi R, Ceresa D. Cytomegalovirus infections of the nervous system. Intervirology. 1997;40:85-97.
27. Gray F, Belec L, Lescs MC, Chretien F, Ciardi A, Hassine D, Flament-Saillour M; de Truchis P; Clair B; Scaravilii F. Varicelia-zoster virus infection of the central nervous system in the acquired immune deficiency syndrome. Brain. 1994; 117(pt 5):987-999.
28. Rodriguez MM, Delgado PI, Petito CK. Epstein-Barr virus-associated primary central nervous system iymphoma in a child with the acquired immunodeficiency syndrome: a case report and review of the literature. Arch Pathol Lab Med. 1997; 121:1287-1291.
29. Sauerbrei A, Eichhorn U, Hottenrott G, Wutzler P. Virological diagnosis of herpes simplex encephalitis. J Clin Virol. 2000;17:31-36.
30. Kimberlin DW, Whitley RJ. Human herpesvirus-6: neurologic implications of a newly-described viral pathogen. J Neurovirol. 1998;4:474-485.
31. Whitley RJ, Lakeman F. Herpes simplex virus infections of the central nervous system: therapeutic and diagnostic considerations. Clin Infect Dis. 1995;20:414-420.
32. Kiapper PE, Cleator GM, Longson M. Mild forms of herpes encephalitis. J Neurol Neurosurg Psychiatry. 1984;47:1247-1250.
33. Kapur N, Barker S, Burrows EH, Ellison D, Brice J, Illis LS, Scholey K, Colbourn C, Wilson B, Loates M. Herpes simplex encephalitis: long term magnetic resonance imaging and neuropsychological profile. J Neurol Neurosurg Psychiatry. 1994;57:1334-1342.
34. Hokkanen L, Launes J. Cognitive outcome in acute sporadic encephalitis. Neuropsychol Rev. 2000;10:151-167.
35. Wise TN, Le Buffe FP, Granger SI. Meningo-encephalitis presenting as an acute paranoid psychosis. Int J Psychiatry Med. 1977;8:405-414.
36. Howard JS III. Herpes encephalitis, schizophrenia and the crossroads of psychiatry. Integr Physiol Behav Sci. 1996;31:219-223.
37. Schlitt M, Lakeman FD, Whitley RJ. Psychosis and herpes simplex encephalitis. South Med J. 1985;78:1347-1350.
38. Kudelova M, Rajcani J, Pogady J, Sramka M. Herpes simplex virus DNA in the brain of psychotic patients. Acta Virol. 1988;32:455-460.
39. Moises HW, Ruger R, Reynolds GP, Fleckenstein B. Human cytomegalovirus DNA in the temporal cortex of a schizophrenic patient. Eur Arch Psychiatry Neurosci. 1988;238:110-113.
40. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001;58:1032-1037.
41. Pelonero AL, Pandurangi AK, Calabrese VP. Serum IgG antibody to herpes viruses in schizophrenia. Psychiatry Res. 1990;33:11-17.
42. Srkanth S, Ravi V, Poornima KS, Shetty KT, Gangadhar BN, Janakiramaiah N. Viral antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic severity. Biol Psychiatry. 1994;36:517-521.
43. Bartova L, Rajcani J, Pogady J. Herpes simplex virus antibodies in the cerebrospinal fluid of schizophrenic patients. Acta Virol. 1987;31:443-446.
44. Fux M, Sarov I, Ginot Y, Sarov B. Herpes simplex virus and cytomegalovirus in the serum of schizophrenic patients versus other psychosis and normal controls. Isr J Psychiatry Relat Sci. 1992;29:33-35.
45. DeLisi LE, Smith SB, Hamovit JR, Maxwell ME, Goldin LR, Dingman CW, Gershon ES. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. Psychol Med. 1986;16:757-763.
46. King DJ, Cooper SJ, Earle JA, Martin SJ, McFerran NV, Rima BK, Wisdom GB. A survey of serum antibodies to eight common viruses in psychiatric patients. Br J Psychiatry. 1985;147:137-144.
47. Yolken RH, Torrey EF. Viruses, schizophrenia and bipolar disorder. Clin Microbiol Rev. 1995;8:131-145.
48. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebocontrolled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry. 2001;158:2071-2074.
49. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24:1-10.
50. Kay SR, Opler LA, Lindenmayer JP. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl. November 1989: 59-67.
51. Randolph C. RBANS Manual: Repeatable Battery for the Assessment of Neuropsychological Status. San Antonio, Tex: Psychological Corp (Harcourt); 1998.
52. Gold JM, Queern C, Iannone VN, Buchanan RW. Repeatable Battery for the Assessment of Neuropsychological Status as a screening test in schizophrenia, I: sensitivity, reliability, and validity. Am J Psychiatry. 1999;156:1944-1950.
53. Buka SL, Goldstein JM, Seidman LJ, Tsuang MT. Maternal recall of pregnancy history: accuracy and bias in schizophrenia research. Schizophr Bull. 2000;26: 335-350.
54. Bergstrom T, Trybala E. Antigenic differences between HSV-1 and HSV-2 glycoproteins and their importance for type-specific serology. Intervirology. 1996; 39:176-184.
55. Ribes JA, Smith A, Hayes M, Baker DJ, Winters JL. Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian Diagnostics. J Clin Microbiol. 2002;40:1071-1072.
56. HerpesSelect 1 ELISA IgG and HerpesSelect 2 IgG [package insert]. Cypress, Calif: Focus Laboratories; 2000.
57. Donohoe G, Owens N, O'Donnell C, Burke T, Moore L, Tobin A, O'Callaghan E. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry. 2001;16:293-298.
58. Leng NR, Parkin AJ. Double dissociation of frontal dysfunction in organic amnesia. Br J Clin Psychol. 1988;27(pt 4):359-362.
59. Shoqeirat MA, Mayes A, MacDonald C, Meudell P, Pickering A. Performance on tests sensitive to frontal lobe lesions by patients with organic amnesia: Leng and Parkin revisited. Br J Clin Psychol. 1990;29(pt 4):401-408.
60. Utley TF, Ogden JA, Gibb A, McGrath N, Anderson NE. The long-term neuropsychological outcome of herpes simplex encephalitis in a series of unselected survivors. Neuropsychiatry Neuropsychol Behav Neurol. 1997;10:180-189.
61. Cagnin A, Myers R, Gunn RN, Lawrence AD, Stevens T, Kreutzberg GW, Jones T, Benati RB. In vivo visualization of activated glia by [11C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain. 2001;124(pt 10):2014-2027.
62. Pearlson GD, Marsh L. Structural brain imaging in schizophrenia: a selective review. Biol Psychiatry. 1999;46:627-649.
63. Caparros-Lefebvre D, Girard-Buttaz I, Reboul S, Lebert F, Cabaret M, Verier A, Steinling M, Pruvo JP, Petit H. Cognitive and psychiatric impairment in herpes simplex virus encephalitis suggest involvement of the amygdalo-frontal pathways. J Neurol. 1996;243:248-256.
64. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman D, Weinberger DR. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917-6922.